Objetivo Human pluripotent stem cells (hPSCs) and hPSCs-derived differentiated cells, such as cardiomyocytes and neuronal cells, are rapidly advancing discoveries in drug screening and development processes and hold much promise for personalised regenerative medicine. The affordable mass production of industrial-grade high quality hPSCs will enable meeting the research and clinical demands of the rapidly growing stem cell market. Accellta Ltd. offers a range of innovative solutions for culturing mass quantities of premium quality stem cells in a cost-effective manner. These solutions are the result of research dated since 1998 at the Stem Cell Centre at the Technion – Israel Institute of Technology. As a newly developed SME, this company has exceptional expertise in innovative hPSC culturing solutions, including growing stem cells in 3D suspension, with unique, animal-free reagents. These technologies are protected by numerous pioneering, granted and acknowledged patents and since its establishment in 2012. This SME already succeeded to license its IP to multi-national cell research companies. Accellta's future vision is to become a leading provider of premium quality differentiated cell lines and services to customers, which include pharmaceutical and biomedical companies. Despite the huge market potential, proper industry and market research plan is essential and organizing a professionally conducted study, using proper consultation and market research databases, is of the utmost importance. Understanding the market's direction and demands would provide the directives in which the company can proceed and find success. Accellta has the know-how, intellectual property, team and infrastructure required to emerge as a leader in this field. The company's remarkably unique techniques in pluripotent stem cell culturing would provide high quality hPSCs-derived differentiated cells will advance drug development and regenerative therapies. Ámbito científico medical and health sciencesbasic medicinepharmacology and pharmacydrug discoveryengineering and technologymechanical engineeringmanufacturing engineeringnatural sciencescomputer and information sciencesdatabasesmedical and health sciencesmedical biotechnologycells technologiesstem cellsmedical and health sciencesbasic medicinetoxicology Programa(s) H2020-EU.2.1.4. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Biotechnology Main Programme H2020-EU.2.3.1. - Mainstreaming SME support, especially through a dedicated instrument Tema(s) BIOTEC-5a-2014-1 - SME boosting biotechnology-based industrial processes driving competitiveness and sustainability Convocatoria de propuestas H2020-SMEInst-2014-2015 Consulte otros proyectos de esta convocatoria Convocatoria de subcontratación H2020-SMEINST-1-2014 Régimen de financiación SME-1 - SME instrument phase 1 Coordinador ACCELLTA LTD Aportación neta de la UEn € 50 000,00 Dirección MALAT BUILDING - 3rd floor - TECHNION CITY 3200004 HAIFA Israel Ver en el mapa Pyme Organización definida por ella misma como pequeña y mediana empresa (pyme) en el momento de la firma del acuerdo de subvención. Sí Tipo de actividad Private for-profit entities (excluding Higher or Secondary Education Establishments) Enlaces Contactar con la organización Opens in new window Participación en los programas de I+D de la UE Opens in new window Red de colaboración de HORIZON Opens in new window Coste total € 71 429,00
